Braveheart Bio

In partnership with Hengrui Pharma, we're pleased to share positive Phase 2 results for BHB/HRS-1893 in non-obstructive hypertrophic cardiomyopathy, presented today at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology. The data suggest a potentially disease-modifying treatment approach in nHCM, supported by rapid and sustained reductions in key biomarkers, structural remodeling, and meaningful improvements in symptoms. The rapid and meaningful responses across these endpoints suggest we may be engaging the underlying pathophysiology in a unique and direct way, and we plan to evaluate this approach at scale in an upcoming global registrational study. Learn more here: https://lnkd.in/eCAzGGp8

Braveheart Bio joins the cardiology community in mourning the loss of Dr. Eugene Braunwald, a defining figure in modern cardiology. Dr. Braunwald's pioneering research revolutionized our understanding and treatment of cardiovascular disease. He was among the first to characterize idiopathic hypertrophic subaortic stenosis, the condition we now call hypertrophic cardiomyopathy (HCM), and his work shaped how generations of physicians understand, diagnose, and treat patients living with it. We are committed to honoring that legacy through our work to develop meaningful treatment options for patients with HCM.

Today, along with our partner Hengrui Pharma, we're pleased to share positive Phase 2 results for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, presented at the American College of Cardiology's Annual Scientific Session.    The data suggest best-in-class potential across efficacy, safety, and ease-of-use. HRS/BHB-1893 demonstrated deep and rapid reductions in obstruction as early as day 2, with no serious adverse events reported. Notably, 89% of patients were well served by 40 or 60 mg doses, suggesting the ability to adopt a simplified dosing regimen with little or no titration.    These results support our planned initiation of a global pivotal clinical study in 2026. Learn more here: https://lnkd.in/eKQfSWfb

We're excited to welcome Emil deGoma, M.D., as Braveheart’s new Chief Medical Officer as we enter the next phase of development for BHB-1893.    Emil brings deep expertise from his background as an academic cardiologist and industry leader advancing innovative cardiovascular medicines.     We're thrilled to welcome Emil to the team at this pivotal moment in our development. Learn more here: https://lnkd.in/eFvsgFph

As we prepare to advance BHB-1893 into global Phase 3 development, we're proud to announce two leadership updates. Marc Evanchik has been promoted to Chief Scientific Officer. Marc has more than 25 years of expertise in the development of novel medicines and particularly cardiac myosin inhibitors. His work was instrumental in advancing the first-in-class cardiac myosin inhibitor for hypertrophic cardiomyopathy. In addition, Brittany de Temple has joined as Senior Vice President of Development Operations to lead operational strategy and execution of our expanding clinical development programs. Brittany brings over 20 years of experience in global clinical development across multiple therapeutic areas. We congratulate and welcome Marc and Brittany to these roles as we grow and progress as a company. Learn more here: https://lnkd.in/eQYwqkMR

Our CEO and President, Travis Murdoch, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 7:30 a.m. PT / 10:30 a.m. ET. He will provide an update on our progress developing novel therapeutics for hypertrophic cardiomyopathy and our late-stage clinical program for BHB-1893. A webcast will be available through our website – www.braveheart.bio – with an archived version available following the presentation. 

Today, Braveheart Bio launches to transform the care of hypertrophic cardiomyopathy (HCM) and related conditions.    We’re immensely grateful for the support of our investors a16z Bio + Health, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences, our experienced and talented team. We look forward to sharing more as we aim to move into late-stage clinical development in 2026.      Read more on our website: https://lnkd.in/etUNjXgp

Excited to announce the official launch of Braveheart Bio today. A big thank you to our investors, for the work in identifying our lead asset BHB-1893, supporting us in the Series A, and on the board. I had the privilege of working with Chris Viehbacher as the head of Biogen’s West Coast Hub, and I’m grateful he’s agreed to be part of this journey as Chair. I’m especially proud and thankful of the team we’ve put together! If you’re reading this and our story is compelling to you—we're going to be growing. You could be part of it. Keep an eye on our website for updates. https://lnkd.in/gP_PV-_3